Live Analyst Rating Changes 8035 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Cory Jubinville, PhD
LIFE
Cory Jubinville, PhD
LifeSci Capital
Wall Street Analyst
★★★★★
#58
on 13Foresight · ranked by our own returns
69%
Success Rate
+28.2%
Average Return
9 of 13 calls profitable · +94.8% vs benchmark
📈 Across the calls we could measure, roughly 69% of Cory Jubinville, PhD's ratings turned a profit when each position was held for 1 year — averaging +28.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

54 Buy 2 Hold 0 Sell
Cory's Stock Coverage 11 ratings · 2026-07-10
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
PRME
Prime Medicine, Inc.
 Jun 23, 2026 BUY Strong Buy
+127.3% avg upside
16 analysts
$6.00
50.36% Upside
 +23.2%
TNYA
Tenaya Therapeutics
 Jun 03, 2026 BUY Strong Buy
+1067.5% avg upside
11 analysts
$4.00
362.13% Upside
 +10.7%
MREO
Mereo Biopharma Group Plc
 Jan 12, 2026 HOLD Strong Buy
+1095.2% avg upside
11 analysts
 — -57.9%
CRNX
Crinetics Pharmaceuticals
 Jan 05, 2026 BUY Strong Buy
-1.9% avg upside
21 analysts
$99.00
135.50% Upside
 +73.3%
SION
Sionna Therapeutics, Inc.
 Dec 23, 2025 BUY Strong Buy
+21.1% avg upside
11 analysts
$60.00
39.20% Upside
 +1.3%
IKT
Inhibikase Therapeutics
 Dec 01, 2025 BUY Strong Buy
+196.1% avg upside
8 analysts
$5.00
152.44% Upside
 +36.0%
TECX
Tectonic Therapeutic
 Nov 18, 2025 BUY Strong Buy
+59.8% avg upside
24 analysts
$88.00
149.93% Upside
 +80.1%
RCKT
Rocket Pharmaceuticals
 Nov 07, 2025 BUY Buy
+293.4% avg upside
29 analysts
$9.00
125.61% Upside
 -6.6%
TARS
Tarsus Pharmaceuticals
 Nov 05, 2025 BUY Strong Buy
+17.9% avg upside
16 analysts
$84.00
25.19% Upside
 -14.8%
LRMR
Larimar Therapeutics
 Nov 05, 2025 BUY Strong Buy
+343.7% avg upside
22 analysts
$22.00
568.67% Upside
 +12.1%
LQDA
Liquidia Technologies
 Nov 03, 2025 BUY Strong Buy
-30.3% avg upside
15 analysts
$67.00
15.47% Downside
 +209.0%
🔒 6 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Cory Jubinville, PhD — Frequently Asked Questions
How accurate are Cory Jubinville, PhD's stock ratings?
Based on the calls 13Foresight could measure, about 67% of Cory's ratings were profitable over a one-year hold, with an average return of +28.6% per rating, or +97.5% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Cory ranked on 13Foresight?
Cory Jubinville, PhD is currently ranked #58 with a 5-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Cory cover?
Cory most recently has ratings on PRME, TNYA, MREO, CRNX, SION, IKT, TECX, RCKT, TARS, LRMR, LQDA. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.